Clinical Trial Detail

NCT ID NCT03121417
Title Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic Non-small Cell Lung Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Emory University
Indications

lung non-small cell carcinoma

Therapies

Nivolumab

Age Groups: senior adult

No variant requirements are available.